Chongqing Zhifei Biological Products Co., Ltd.

XSEC:300122 Stock Report

Market Cap: CN¥58.2b

Chongqing Zhifei Biological Products Past Earnings Performance

Past criteria checks 2/6

Chongqing Zhifei Biological Products has been growing earnings at an average annual rate of 16.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 30% per year. Chongqing Zhifei Biological Products's return on equity is 11.7%, and it has net margins of 10.1%.

Key information

16.2%

Earnings growth rate

16.2%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate30.0%
Return on equity11.7%
Net Margin10.1%
Next Earnings Update22 Apr 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Chongqing Zhifei Biological Products makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300122 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2436,4323,6903,6701,015
30 Jun 2446,7316,0443,540993
31 Mar 2453,1417,4963,778989
31 Dec 2352,9188,0703,508968
30 Sep 2349,7128,4623,702895
30 Jun 2344,3568,0703,377903
31 Mar 2340,5967,6483,124907
01 Jan 2338,2647,5393,016854
30 Sep 2236,6477,4122,727920
30 Jun 2235,8358,4472,615778
31 Mar 2235,56711,1932,489652
31 Dec 2130,65210,2092,312553
30 Sep 2125,9699,2261,977319
30 Jun 2121,3687,2871,838356
31 Mar 2116,4823,7231,629314
31 Dec 2015,1903,3011,493300
30 Sep 2013,9713,0821,539286
30 Jun 2012,5422,7241,447208
31 Mar 2010,9282,3811,398186
31 Dec 1910,5872,3661,346170
30 Sep 199,4002,1281,297160
30 Jun 198,1951,9161,165167
31 Mar 196,6841,6941,041152
31 Dec 185,2281,451956143
30 Sep 184,0681,234690166
30 Jun 182,969943607122
31 Mar 182,019632482100
31 Dec 171,34343243778
30 Sep 179423114510
30 Jun 177071924060
31 Mar 17464343810
31 Dec 16446333700
30 Sep 16431443530
30 Jun 165121013710
31 Mar 166602093650
31 Dec 157131973690
30 Sep 157791723810
30 Jun 158051603520
31 Mar 158351533460
31 Dec 148011483270
30 Sep 147771363200
30 Jun 147351243100
31 Mar 147581323120

Quality Earnings: 300122 has high quality earnings.

Growing Profit Margin: 300122's current net profit margins (10.1%) are lower than last year (17%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300122's earnings have grown by 16.2% per year over the past 5 years.

Accelerating Growth: 300122's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300122 had negative earnings growth (-56.4%) over the past year, making it difficult to compare to the Biotechs industry average (1.3%).

Return on Equity

High ROE: 300122's Return on Equity (11.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 04:04
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chongqing Zhifei Biological Products Co., Ltd. is covered by 25 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Xin ZhangAJ Securities Co., Ltd
Bo LiBofA Global Research
Yuanrui LiuChangjiang Securities Co. LTD.